Retatrutide is not FDA-approved — here is what that means
As of July 2026, retatrutide does not have an FDA approval date.
It is an investigational drug. That means it has not completed the clinical trial process the FDA requires before a medicine can be legally marketed and prescribed in the United States.
Investigational status is not a red flag. Every drug currently on pharmacy shelves — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — went through this same stage before approval.
What investigational status does mean: retatrutide cannot be legitimately obtained through a licensed pharmacy or clinic in the US right now. Any supplier claiming otherwise is selling an unverified compound.
Where retatrutide stands in the trial process
Drug development moves through phases: Phase 1 (safety in a small group), Phase 2 (dose-finding and early efficacy), Phase 3 (large-scale efficacy and safety), then FDA review.
Retatrutide completed Phase 2 in 2023. Those results were published in the New England Journal of Medicine.
It is currently in Phase 3. The TRIUMPH program — four large randomized trials enrolling more than 5,800 participants — is designed to generate the data the FDA needs to review a formal approval application.
Phase 3 trials for obesity drugs typically run 72–96 weeks to capture both the weight-loss trajectory and longer-term safety data. TRIUMPH began enrolling in late 2023 and 2024, which puts primary endpoint data in the 2026–2027 window.
After Phase 3 data are collected, Eli Lilly (the developer) must compile a New Drug Application (NDA) and submit it to the FDA. FDA review typically takes 6–12 months under standard review, or as little as 6 months under Priority Review if granted.
What Phase 2 showed — and why the FDA still needs Phase 3
Phase 2 enrolled 338 adults with obesity. After 48 weeks, participants on the highest dose (12 mg/week) lost an average of 24.2% of their body weight — a figure larger than any obesity drug had produced in a Phase 2 trial at the time.
Lower doses also showed meaningful results: 8 mg produced approximately 17% weight loss; 4 mg produced approximately 8.7%.
Phase 2 is designed to find the right dose and confirm early safety signals — not to determine whether a drug is safe and effective for the broader population. Phase 3 is built for that. It requires a much larger sample, longer follow-up, and pre-specified primary endpoints.
The FDA's standard for approval is not "impressive Phase 2 data." It is "adequate and well-controlled investigations" — the plural is intentional. That is why TRIUMPH runs four separate trials.
Phase 2 weight-loss data by dose arm
The table below summarizes the Phase 2 results published in the New England Journal of Medicine (2023). All figures are for participants without type 2 diabetes. These are Phase 2 results; Phase 3 results may differ.
| Dose (weekly SC) | Mean weight change at 48 wk | Notes |
|---|---|---|
| Placebo | −2.1% | Run-in: 4 mg × 4 wk; dose escalation protocol |
| 1 mg | −7.9% | Starting ramp: 2 mg × 4 wk → target |
| 4 mg | −8.7% | Starting ramp: 2 mg × 4 wk → target |
| 8 mg | −17.1% | Starting ramp: 2 mg × 4 wk → target |
| 12 mg | −24.2% | Highest dose arm; starting ramp: 2 mg → 4 → 8 → 12 mg |
Realistic FDA approval timeline
No one outside Eli Lilly and the FDA knows exactly when — or whether — retatrutide will be approved. Trial outcomes are not guaranteed.
Based on public information about the TRIUMPH trial design, enrollment timelines, and typical NDA review periods, a plausible scenario looks like this:
2026–2027: TRIUMPH trials complete and primary endpoint data are analyzed.
2027–2028: Eli Lilly submits an NDA to the FDA, assuming results are positive. FDA has 60 days to accept or refuse to file. If accepted, standard review is 10–12 months; Priority Review (if granted) is 6 months.
2028–2029: Potential approval window, if trials succeed and the FDA does not require additional studies.
This is an estimate, not a prediction. Regulatory timelines shift. Eli Lilly has not announced a projected submission date.
How retatrutide compares to approved GLP-1 drugs
Two GLP-1 class drugs are FDA-approved for chronic weight management as of mid-2026: semaglutide (Wegovy, approved 2021) and tirzepatide (Zepbound, approved November 2023).
Tirzepatide targets two receptors — GIP and GLP-1. In the SURMOUNT-1 trial, it produced an average of 20.9% weight loss over 72 weeks.
Retatrutide targets three receptors: GIP, GLP-1, and glucagon. The glucagon component is thought to increase energy expenditure on top of appetite suppression. That is the mechanistic reason its Phase 2 numbers exceeded tirzepatide's Phase 2 numbers.
Cross-trial comparisons are not head-to-head data. Different trials, different populations, different designs. They cannot tell you which drug is "better." What they can tell you is that retatrutide warrants the Phase 3 investment it is currently receiving.
If approved, retatrutide would enter a market that already has two effective approved options. The clinical question — which patients benefit most from a triple agonist — is one the TRIUMPH program is designed to help answer.
What "not FDA-approved" means for your clinic visit
If you are currently on semaglutide or tirzepatide and wondering whether to wait for retatrutide: those are decisions to make with your prescribing clinician, not based on Phase 2 data from a drug that has not yet completed trials.
If someone is offering you retatrutide for purchase or injection today, it is not coming from a licensed US pharmacy. It may be a research chemical, a compounded compound of uncertain purity, or a counterfeit. None of those have passed the safety and manufacturing standards the FDA requires.
The most useful thing you can do right now is track what your clinician prescribes, monitor your biomarkers, and revisit the question if and when Phase 3 results are published and an NDA is filed.
The bottom line
Retatrutide has no FDA approval date. It is in Phase 3 trials as of mid-2026.
Phase 2 data are compelling — 24.2% weight loss at the highest dose is a clinical benchmark. But Phase 2 data are not approval data.
If TRIUMPH trials succeed and Eli Lilly files an NDA, a realistic approval window is 2028–2029. That could shift in either direction.
Until approval, retatrutide cannot legally be prescribed or dispensed in the US. The approved options for chronic weight management — semaglutide and tirzepatide — have robust Phase 3 and post-market safety data behind them.